Navigation Links
Original Drugs Pave the Way for Follow-on Biologics
Date:6/12/2013

MOUNTAIN VIEW, Calif., June 12, 2013 /PRNewswire/ --

WHEN:       

11:00 a.m. EDT on Tuesday, June 18, 2013

LOCATION:  

Online, with complimentary registration

SPEAKER:     

Healthcare Industry Manager Sandhya Kamath

With the impending patent expiries of biologic drugs, there is huge market potential for subsequent entry biologics. A strong integration of research and development with marketing is key to success.  This Technical Insights analyst briefing will highlight the latest technology advancements, as well as the trends shaping the future of this market.

Attend this webinar to:

  • Learn about the growth of follow-on biologics
  • Identify the drivers and restraints
  • Discover trends in technology development

This briefing will benefit pharmaceutical companies and specialty biotechnology firms by discussing emerging trends and providing forward-looking projections.

Supporting Quote

"By 2015, the follow-on biologics market is expected to transition to a stage of high growth," said Frost & Sullivan Healthcare Industry Manager Sandhya Kamath.  "With manufacturing advancements and regulatory guidelines falling into place, there is scope for more companies to venture into this space."

Supporting Resources

For more information about Frost & Sullivan's Technical Insights practice, please visit: http://www.technicalinsights.frost.com

Registration

  • To attend the briefing, email britni.myers@frost.com your full name, job title, company name, company telephone number, company email address and website, city, state and country.
  • Receive a recorded version of the briefing anytime by submitting the aforementioned contact details.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:        Gain access to visionary innovation

Contact:
Britni Myers
Frost & Sullivan
+1.210.477.8481
britni.myers@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
2. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
3. Ophthalmic Drugs: World Market Prospects 2012-2022
4. Antithrombotic/Anticoagulant Drugs: World Market 2012-2022
5. INTAC™ Technology Combats Misuse of Extended Release Drugs
6. Contract Research Organizations Set to Experience Rapid Growth as Development Costs for New Drugs Continue to Rise
7. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
8. Bilcare and CSIR to Partner on nonClonableID Technology for Authentication of Drugs
9. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
10. Genitourinary Drugs: Technologies and Global Markets
11. Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLOs Seven Nosologies Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... -- Mitsubishi Tanabe Pharma Corporation (Head Office: ... Masayuki Mitsuka ) has presented data that show ... in 10-14 day cycles for 48 weeks experienced significantly ... Rating Scale-Revised (ALSFRS-R). The data were presented at the ... Dublin, Ireland . In the ...
(Date:12/9/2016)... HARRISBURG, Pa. , Dec. 9, 2016 ... today announced temporary regulations for medical marijuana dispensaries under ... The Pennsylvania Bulletin , and are now available ... what is needed in the plan for operation; process ... the dispensary; as well as where the dispensary facilities ...
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 ... Market Outlook to 2022", provides key market data on ... in millions of US dollars, volume (in units) and ... Femtosecond Lasers and YAG Lasers. The report also ... of these market segements, and global corporate-level profiles of ...
Breaking Medicine Technology:
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... 08, 2016 , ... With the increasing demand for dental implants, the National ... campaign to inform dentists and patients about the safety issues related to dental restorations. ... in the U.S. is projected to reach $6.4 billion in 2018 with more than ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... for customers and employees that are both engaging and easy to use. Coming ... Technology, the software company revealed today its plans to roll out new AI-powered ...
(Date:12/8/2016)... ... , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services from ... Messina. , Among the recognitions, the American College of Surgeons' (ACS) named the ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... soon after surgery as possible. With this in mind, SIGVARIS has created a ... or blood clot) during bed rest and provide the benefits of graduated compression ...
Breaking Medicine News(10 mins):